Starting July 1, Medicare begins coverage of certain GLP-1 medications when they are prescribed solely for weight loss. Multiple outlets report that this is the first time Medicare will pay for GLP-1 drugs used for obesity- or weight-loss–related purposes without requiring an additional qualifying condition. Coverage applies to eligible Medicare beneficiaries under a temporary federal program.
CBS News and others say the program is structured so that beneficiaries pay a $50 monthly copay for the covered GLP-1s. The coverage follows a previous limitation: until now, Medicare generally covered GLP-1s only for specific conditions such as type 2 diabetes, and not for weight-loss alone.
Several sources also emphasize the restricted nature of the program. It covers a selection of GLP-1 drugs and only under criteria tied to weight-loss use. Reporting also notes uncertainty about broader program costs, since the initiative is temporary and runs through 2027, even as beneficiaries gain access to lower-cost options for weight management.
